Literature DB >> 24591336

Diastrophic dysplasia sulfate transporter (SLC26A2) is expressed in the adrenal cortex and regulates aldosterone secretion.

Ariadni Spyroglou1, Tarik Bozoglu, Rajesh Rawal, Fabio De Leonardis, Christina Sterner, Sheerazed Boulkroun, Arndt G Benecke, Luca Monti, Maria-Christina Zennaro, Ann-Kristin Petersen, Angela Döring, Antonio Rossi, Martin Bidlingmaier, Richard Warth, Christian Gieger, Martin Reincke, Felix Beuschlein.   

Abstract

Elucidation of the molecular mechanisms leading to autonomous aldosterone secretion is a prerequisite to define potential targets and biomarkers in the context of primary aldosteronism. After a genome-wide association study with subjects from the population-based Cooperative Health Research in the Region of Augsburg F4 survey, we observed a highly significant association (P=6.78×10(-11)) between the aldosterone to renin ratio and a locus at 5q32. Hypothesizing that this locus may contain genes of relevance for the pathogenesis of primary aldosteronism, we investigated solute carrier family 26 member 2 (SLC26A2), a protein with known transport activity for sulfate and other cations. Within murine tissues, adrenal glands showed the highest expression levels for SLC26A2, which was significantly downregulated on in vivo stimulation with angiotensin II and potassium. SLC26A2 expression was found to be significantly lower in aldosterone-producing adenomas in comparison with normal adrenal glands. In adrenocortical NCI-H295R cells, specific knockdown of SLC26A2 resulted in a highly significant increase in aldosterone secretion. Concomitantly, expression of steroidogenic enzymes, as well as upstream effectors including transcription factors such as NR4A1, CAMK1, and intracellular Ca(2+) content, was upregulated in knockdown cells. To substantiate further these findings in an SLC26A2 mutant mouse model, aldosterone output proved to be increased in a sex-specific manner. In summary, these findings point toward a possible effect of SLC26A2 in the regulation of aldosterone secretion potentially involved in the pathogenesis of primary aldosteronism.

Entities:  

Keywords:  aldosterone to renin ratio; calcium signaling; genome-wide association study; knockout mice; primary hyperaldosteronism; solute carrier family 26 (sulfate transporter), member 2 protein, human

Mesh:

Substances:

Year:  2014        PMID: 24591336     DOI: 10.1161/HYPERTENSIONAHA.113.02504

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  5 in total

1.  Chemogenetic activation of adrenocortical Gq signaling causes hyperaldosteronism and disrupts functional zonation.

Authors:  Matthew J Taylor; Matthew R Ullenbruch; Emily C Frucci; Juilee Rege; Mark S Ansorge; Celso E Gomez-Sanchez; Salma Begum; Edward Laufer; David T Breault; William E Rainey
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

2.  Genetic screening of hypertensive patients with aldosterone hypersecretion under conditions of stress.

Authors:  Niki Mourtzi; Amalia Sertedaki; Athina Markou; George P Piaditis; Nicholas Katsanis; Joanne Traeger-Synodinos; Constantine Tsigos; Evangelia Charmandari
Journal:  Hormones (Athens)       Date:  2022-08-31       Impact factor: 3.419

3.  X-chromosome variants are associated with aldosterone producing adenomas.

Authors:  Oliver Gimm; Peter Söderkvist; Ravi Kumar Dutta; Malin Larsson; Thomas Arnesen; Anette Heie; Martin Walz; Piero Alesina
Journal:  Sci Rep       Date:  2021-05-18       Impact factor: 4.379

Review 4.  Genetic causes of primary aldosteronism.

Authors:  Eric Seidel; Julia Schewe; Ute I Scholl
Journal:  Exp Mol Med       Date:  2019-11-06       Impact factor: 8.718

5.  Suppressing UPR-dependent overactivation of FGFR3 signaling ameliorates SLC26A2-deficient chondrodysplasias.

Authors:  Chao Zheng; Xisheng Lin; Xiaolong Xu; Cheng Wang; Jinru Zhou; Bo Gao; Jing Fan; Weiguang Lu; Yaqian Hu; Qiang Jie; Zhuojing Luo; Liu Yang
Journal:  EBioMedicine       Date:  2019-01-23       Impact factor: 8.143

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.